Skip to Main Content


Current Issue
Volume 4,
Issue 14,
July 28, 2020


Message from ASH President on Diversity, Equity, and Inclusion

Authors and Reviewers: New COVID-19 Announcement

Featured Content

Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?

Sickle cell disease (SCD) is arguably one of the best-understood diseases from a molecular perspective, yet patients with this disorder suffer from a myriad of complications. In a timely review, Telen addresses the question of curative vs targeted therapy in patients with SCD.

T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor?

In a review, Kroeze and colleagues discuss the question of the cell of origin of T-cell lymphoblastic leukemia and lymphoma. Particularly, they discuss recent findings with respect to clinical presentation, genetic predisposition, and the acquisition of additional mutations with the aim of finding common pathways to target for future novel therapies.

Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma

Assessment of minimal residual disease (MRD) in patients with lymphoid malignancies such as multiple myeloma is widely available. Martínez-López and colleagues detail a single center’s use of MRD assessments and how these assessments predict clinical outcomes.

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study

Delfau-Larue and colleagues evaluated the use of lenalidomide and rituximab as first-line therapy for patients with untreated follicular lymphoma. This combination induced an impressive number of patients into a complete molecular response and compared favorably to other approaches.

High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma

CD19 chimeric antigen receptor (CAR) T-cell–based immunotherapy has been applied to a diverse array of patients with diffuse large B-cell lymphoma. Dean and colleagues explored the relationship between metabolic activity of the tumor and response to CD19 CAR T-cell therapy, with interesting clinical findings.

Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatawl outcome

Fetal and neonatal alloimmune thrombocytopenia is typically caused by antibodies against human platelet antigen 1a. In a Systematic Review, Kjeldsen-Kragh and colleagues explore the role of maternal HLA expression, the development of antibodies, and the clinical outcome of patients with this disease.

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal